Zhejiang Hisoar Pharmaceutical Co.,Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Zhejiang Hisoar Pharmaceutical Co.,Ltd.

26 YRS

Zhejiang, China

CNY 1618.7 Million

59940 m²

Over 1000 people

Main Products: Clindamycin Phosphate / Clindamycin Palmitate HCl / Clindamycin Hydrochloride Monohydrate / Meropenem / Thiamphenicol / Amorolfine Hydrochloride / Bifendate / Phenylephrine Hydrochloride / Metroprolol Succinate / Quetiapine Fumarate / Repaglinide / Sulfasalazine / Sulfapyridine / Voglibose / Blue Base P-3R

Zhejiang, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

ABOUT US

Zhejiang Hisoar Pharmaceutical Co.,Ltd. (hereinafter referred to as Haixiang pharmaceutical, securities code: 002099), located in Taizhou, Zhejiang Province, is a listed company controlled by Donggang group, which mainly produces characteristic APIs, preparations, fine chemicals, dyes and dye intermediates. It is one of the top 100 enterprises with innovation ability in the national pharmaceutical industry Key high-tech enterprises of the national torch plan, the first batch of integrity demonstration enterprises in Zhejiang Province, and excellent self export production enterprises in Zhejiang Province. The company has jurisdiction over Taizhou Qianjin Chemical Co., Ltd., Zhejiang Haixiang Chuannan Pharmaceutical Co., Ltd., Shanghai Haixiang Pharmaceutical Technology Development Co., Ltd., Taizhou Gangxiang Technology Co., Ltd., Gangxiang International Holding (Hong Kong) Co., Ltd., Zhejiang Qilian Environmental Protection Technology Co., Ltd. and Yichang Haixiang Pharmaceutical Co., Ltd. (Preparatory). The company's main products are antibiotics, cardiovascular, hypoglycemic and other APIs, fine chemicals, preparations, dyes and intermediates. More than 70% of pharmaceutical products are exported, and the output of clindamycin series is firmly in the leading position in the world. The company attaches great importance to the construction of EHS and GMP system. Dozens of products have been registered with the US FDA, obtained the EU CEP (COS) certificate, passed the Japanese GMP certification and domestic GMP certification. Dye products are exported to more than 30 countries and regions such as Europe, America and Asia. The leading product reactive brilliant blue KN-R accounts for more than 60% of the global market share. It is in a leading position in the industry in terms of industrial scale, technical quality and product application. "Dye eight brand" reactive dyes are rated as China's famous brand products and national excellent torch plan projects. They are one of the three famous brand dyes in China. Long term cooperation with world-famous pharmaceutical and dye companies is our development philosophy. Pfizer, Boehringer Ingelheim, BASF, Sanofi, Novartis, Janssen, Sumitomo chemical, destar, Huntsman and other companies are our important partners. Our development strategy is: Based on China, global layout, high-end cooperation and Sino foreign linkage, we will develop into an excellent high-end medical and chemical enterprise covering the whole industrial chain operation of medicine and dyes and the competition of industrial value chain.

Basic Information